Press release
Uterine Fibroids Pipeline Drugs Assessment: Clinical Trails Analysis, Player Profiles, Collaborations, Key Targets, Geographic Focus, and Data Publications, 2018
Uterine Fibroids Pipeline Drugs
Uterine fibroids are the most commonly seen non-cancerous tumors of the female reproductive system. The fibroids otherwise called leiomyomas, uterine myomas or fibromas. These are compact tumors which are made up of smooth muscle and fibrous connective tissue that develops in uterus.
Uterine fibroids most commonly found during routinepelvic examination. Smaller fibroids may not found during the normal examination, ultrasound examination may require. And physicians may suggest the diagnostic imaging techniques such as Ultrasound, saline infusion sonography, MRI or compound tomography for the detection of the fibroids in uterus.
Generally, uterine fibroids treatment may include minimally invasive procedures such as hysterectomy, myomectomy and uterine artery embolization. Gonadotropin-releasing hormones are used to lower the levels of estrogen and triggers “medical menopause” and sometimes these hormones shrink the fibroids and make surgical treatment easier. Painkillers may be used to reduce the pain.
A sample of this report is available upon request @
https://www.precisionbusinessinsights.com/market-reports/uterine-fibroids-pipeline-drugs-assessment/#ulp-4H8Z4LpNMLEuOnnx
Segmentation:
Uterine fibroids pipeline drugs are segmented based on route of administration, trial phase,and company
By route of administration, uterine fibroids pipeline drugs are segmented into
• Oral
• Vaginal
• Others
By trial phase, uterine fibroids pipeline drugs are segmented into
• Pre-clinical phase
• Phase-I
• Phase II
• Phase-III
By company, uterine fibroids pipeline drugs are segmented into
• Repros Therapeutics Inc. (U.S.)
• Bayer AG (Germany)
• Takeda Pharmaceutical Company Ltd (Japan)
• AbbVie Inc. (U.S.)
• KISSEI PHARMACEUTICAL CO.,Ltd. (Japan)
• BioSpecifics Technologies Corporation (U.S.)
• DONGKOOK Pharmaceutical Co., Ltd (Japan)
To view TOC of this report is available upon request @
https://www.precisionbusinessinsights.com/market-reports/uterine-fibroids-pipeline-drugs-assessment/#ulp-c654SbFYO64MsOhu
Space Analysis:
• Bayer AG expected to start its late-stage clinical trials (phase-3) for novel prostaglandin receptor agonist, vilaprisan for the treatment of woman with uterine fibroids in Feb 2018.
• In October 2017, Takeda Pharmaceutical Company Limited announced that phase-3 clinical trials of its TAK-385, a gonadotropin-releasing hormone receptor agonist, met the primary endpoint of infertility to the active control group in the treatment of uterine fibroids in Japan. Furthermore, company is planning to submit results to regulatory authorities in Japan for marketing authorization of relugolix for treatment of uterine fibroids.
Report Description:
Uterine Fibroids Pipeline Drugs Assessment report studies the various therapeutics under clinical development for uterine fibroids treatment along with targets for various drug candidate. The report provides plethora of information pertaining to trail phases, companies involved in the uterine fibroids pipeline drugsdevelopment. This report studies the dynamics of the Uterine Fibroids Pipeline Drugs i.e. drivers, challenges and opportunities which are significantly impacting the product development. The report provides various information pertaining the clinical trials such as designation, grants, patents, and technology among others. Moreover, the report on uterine fibroids pipeline drugs assessment comprehensively presents the geographic location, trial status information along with key players involved in the therapeutics development.
Need more information about this report @
https://www.precisionbusinessinsights.com/market-reports/uterine-fibroids-pipeline-drugs-assessment/#ulp-14mlyhjMGhVjZqa3
Key Features of the Report:
• Provides the information related to universities and research institutes working in the therapeutics development
• Report comprehensively covers the all active and discontinued studies
• Studies the entire pipeline with special emphasis on companies actively involved in the therapeutics development
• Presents the prominent targets for drug development in each stage of clinical trial
• Provides the in-depth analysis on each drug candidates in the clinical trial phases
Get access to full summary @
https://www.precisionbusinessinsights.com/market-reports/uterine-fibroids-pipeline-drugs-assessment/
About Precision Business Insights
Precision Business Insights is one of the leading market research and business consulting firm, which follow a holistic approach to solve needs of the clients. We adopt and implement proven research methodologies to achieve better results. We help our clients by providing actionable insights and strategies to make better decisions. We provide consulting, syndicated and customised market research services based on our client needs.
Contact to Precision Business Insights,
Kemp House,
152 – 160 City Road,
London EC1V 2NX
Email: sales@precisionbusinessinsights.com
Toll Free (US): +1-866-598-1553
Website @ https://www.precisionbusinessinsights.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Uterine Fibroids Pipeline Drugs Assessment: Clinical Trails Analysis, Player Profiles, Collaborations, Key Targets, Geographic Focus, and Data Publications, 2018 here
News-ID: 1040132 • Views: …
More Releases from Precision Business Insights
Gaming Controller Market Rising Demand for Gaming Stations and eSports
According to the Precision Business Insights (PBI), latest report the gaming controller market size was valued at USD 2,382.1 million in 2023, growing at an 8.5% CAGR from 2024 to 2030. The key drivers of the expansion of the global gaming controller include the enhanced gaming experience, technology advancements, consumer preferences and ergonomics, competitive gaming and esports, intuitiveness, and portability of the gaming controllers.
View Full Report: https://www.precisionbusinessinsights.com/market-reports/gaming-controller-market …
Next Generation Dietary Supplements Market Size, Growth Opportunities 2024-2030
According to Precision Business Insights (PBI), the latest report, the global next-generation dietary supplements market was valued at USD 10,752.3 million in 2023 and is expected to grow at a CAGR of 8.8% from 2024-2030. The primary factors that drive the market are the growing demand for rising consumer knowledge of the various health benefits of Next Generation Dietary Supplements, as well as rising disposable income levels, fuel market expansion…
Catamaran Market Increasing Popularity Of Water Sports And Fishing Activities
According to Precision Business Insights (PBI), the latest report, the catamaran market is valued at USD 1,635.7 million in 2023 and is anticipated to grow a CAGR of 4.9% over the forecast period. The primary factors that drive the market are the growing demand for Catamaran pushes the market to enhance efficiency, minimize time consumption, and reduce post-harvest operating losses. Catamaran are good solutions for reducing high labour costs since…
Refrigerated Display Cases Market Size, Share, Growth Trends and Forecast 2024-2 …
According to Precision Business Insights (PBI), latest report, the refrigerated display cases market was valued at USD 8,248.5 million in 2023 and is expected to grow at a 5.1% CAGR from 2024 to 2030. The primary drivers of the expansion of the global refrigerated display cases market include the increasing demand for frozen food and drinks among urban consumers. In addition, growing awareness about environment sustainability and energy efficiency is…
More Releases for Uterine
Uterine Fibroids Symptoms
USA Fibroids Center is here to offer detailed information on https://www.usafibroidcenters.com/blog/uterine-fibroids-symptoms/ and help you discuss the best treatments for uterine fibroids at the clinic.
Find out the best Fibroid Treatment for you!
Treatments for uterine fibroids are accessed in women with problems related to them and show symptoms such as heavy menstrual bleeding, pain or pressure in the pelvis, or infertility and sterility.
…
Bharath Hospital Kottayam Offers Minimally Invasive Treatment for Uterine Fibroi …
Bharath Hospital Kottayam is excited introduce the latest advancement in women's healthcare - the Uterine Fibroid Embolization (UFE) treatment. Uterine fibroids are non-cancerous growths that form in the uterus. They are a common condition among women, especially those of reproductive age. These tumors can vary in size, from small growths to large masses that can distort the shape of the uterus. Although many women with uterine fibroids experience no symptoms,…
Uterine Manipulator Devices Market Report 2018: Segmentation by Type (Donnez Typ …
Global Uterine Manipulator Devices market research report provides company profile for ConMed, Richard Wolf, Bisinger, Planmeca Oy, Ethicon Endosurgery, Cooper Surgical, Hospiiniz International, C. R. Bard and Others.
This market study includes data about consumer perspective, comprehensive analysis, statistics, market share, company performances (Stocks), historical analysis 2012 to 2017, market forecast 2018 to 2025 in terms of volume, revenue, YOY growth rate, and CAGR for the year 2018 to 2025,…
Uterine Fibroids Treatment Market : Hysterectomy to Remain Most Preferred Uterin …
The market for uterine fibroids treatment market is fragmented in nature with a high number of players operating in it across the U.S., states a new market research report by Transparency Market Research. The estimated entry of new players and the increasing research and development activities are some of the key factors that are projected to strengthen the competitive scenario of the market throughout the forecast period. The leading players…
Uterine Leiomyoma (Uterine Fibroids) - Pipeline Review, H2 2018 - Research By Ma …
Uterine Leiomyoma (Uterine Fibroids) - Pipeline Review, H2 2018, provides an overview of the Uterine Leiomyoma (Uterine Fibroids) (Non Malignant Disorders) pipeline landscape.
Uterine Leiomyoma (Uterine Fibroids) - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Uterine Leiomyoma (Uterine Fibroids) (Non Malignant Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers…
Uterine Fibroids Treatment Market: Rising Prevalence of Uterine Fibroids amongst …
The high prevalence of uterine fibroids across the U.S. has created a significant demand for uterine fibroid treatments across the countries. The growing public concern about the occurrence of uterine fibroids, which are also called uterine leiomyoma, have propelled the demand for treatments and solutions to alleviate the pain, excessive bleeding, and pelvic discomfort.
According to the report by Transparency Market Research, the U.S. uterine fibroid treatment market is anticipated to…
